ApoE4-Driven Accumulation of Intraneuronal Oligomerized Aβ42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function by Zepa, Lia et al.
SAGE-HindawiAccess to Research
International Journal of Alzheimer’s Disease
Volume 2011, Article ID 792070, 8 pages
doi:10.4061/2011/792070
Research Article
ApoE4-Driven Accumulation ofIntraneuronalOligomerized
Aβ42 following ActivationoftheAmyloid CascadeInVivo Is
Mediated byaGainof Function
LiaZepa,1 Moran Frenkel,1 Haim Belinson,1 ZehavitKariv-Inbal,1 RakezKayed,2
EliezerMasliah,3 andDaniel M. Michaelson1
1Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
2George P. and Cynthia Woods Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston,
TX 77555-0857, USA
3Departments of Neurosciences and Pathology, University of California San Diego, La Jolla, CA 92093-0624, USA
Correspondence should be addressed to Daniel M. Michaelson, dmichael@post.tau.ac.il
Received 4 October 2010; Revised 21 November 2010; Accepted 3 December 2010
Academic Editor: Katsuhiko Yanagisawa
Copyright © 2011 Lia Zepa et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution License,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Activating the amyloid cascade by inhibiting the Aβ-degrading enzyme neprilysin in targeted replacement mice, which express
either apoE4 orapoE3, results in thespeciﬁc accumulationofoligomerizedAβ42 in hippocampal CA1 neuronsof the apoE4 mice.
We presently investigated the extent to which the apoE4-driven accumulation of Aβ42 and the resulting mitochondrial pathology
are due to either gain or loss of function. This revealed that inhibition of neprilysin for one week triggers the accumulation of
Aβ42 in hippocampal CA1 neurons of the apoE4 mice but not of either the corresponding apoE3 mice or apoE-deﬁcient mice. At
10 days, Aβ42 also accumulated in the CA1 neurons of the apoE-deﬁcient mice but not in those of the apoE3 mice. Mitochondrial
pathology, which in the apoE4 mice is an early pathological consequence following inhibition of neprilyisn, also occurs in the
apoE-deﬁcient but not in the apoE3 mice and the magnitude of this eﬀect correlates with the levels of accumulated Aβ42 and
oligomerized Aβ42 in these mice. These ﬁndings suggest that the rate-limiting step in the pathological eﬀects of apoE4 on CA1
neurons is the accumulation of intracellular oligomerized Aβ42 which is mediated via a gain of function property of apoE4.
1.Introduction
Apolipoprotein E (apoE) is a major brain lipoprotein and
is expressed in humans as three common isoforms that
diﬀer from each other by one or two amino acids; these
isoforms are termed apoE2 (Cys112, Cys158), apoE3 (Cys
112, Arg158), and apoE4 (Arg112, Arg158) [1, 2]. Genetic
and epidemiological studies revealed that the allele ε4o f
apoE is a strong genetic risk factor for early and late
onset of Alzheimer’s disease (AD) [3, 4]. More than 50%
of AD patients carry the apoE ε4 allele which increases
the risk for the disease by 2-3-fold in individuals who
express one such allele and by more than 10-fold in subjects
with two ε4 alleles [5, 6]. Histopathologically, apoE4 is
associated in AD with increased amyloid deposition [7], and
corresponding animal model and in vitro studies revealed
synergistic pathological interactions between Aβ and apoE4
[4, 8–12] that are associated with cognitive deﬁcits [13,
14]. This led to the suggestion that apoE4 potentiates
the neurotoxic eﬀects of Aβ and the amyloid cascade and
drives them above a pathological threshold. The molecular
mechanisms underlying the pathological cross-talk between
Aβ and apoE and the extent to which they also mediate other
pathological hallmarks of apoE4 in AD, such as impaired
neuronal plasticity and repair [15–17] and increased brain
inﬂammation [18], are currently not known. Another key
unresolved issue is whether the pathological eﬀects of apoE4
are due to the gain of a pathological property by apoE4 or
to the loss of a protective function by this molecule, that the
other apoE isoforms have.
We have recently shown that activation of the amyloid
cascade by inhibiting the Aβ-degrading enzyme neprilysin2 International Journal of Alzheimer’s Disease
in targeted replacement mice that express either apoE4 or
apoE3 results in the isoform-speciﬁc accumulation of Aβ42,
oligomerized Aβ42, and apoE in CA1 neurons of the apoE4
mice, which in turn trigger mitochondrial pathology, neu-
rodegeneration, and activation of cell death process [13, 19].
We presently investigate the extent to which the apoE4-
driven intracellular accumulation and oligomerization of
Aβ42 and the resulting mitochondrial impairments are due
to either gain or loss of function of apoE4 relative to the
ADbenignisoform,apoE3.Thiswasperformedbyinhibiting
the Aβ-degrading enzyme neprilysin in apoE-deﬁcient mice
and in corresponding apoE4- and apoE3-targeted replace-
ment mice. This was then followed by investigation of the
resulting eﬀects of apoE deﬁciency on the accumulation and
oligomerization of Aβ42 and the associated neuropathology
in CA1neurons and of the extent to which theyare similar to
those observed in either the apoE4 or the apoE3 mice.
2.Materialsand Methods
2.1. Transgenic Mice and Implantation of Alzet Miniosmotic
Pumps. ApoE-targeted replacement mice (apoE mice), cre-
ated by gene targeting [20], were purchased from Taconic.
The mice were back-crossed to C57BL/6J mice for eight
generations and were homozygous for eitherthe apoE3 (3/3)
or the apoE4 (4/4) allele. ApoE-deﬁcient mice were pur-
chased from Jackson Laboratories and were on the same
background. The experiments were performed utilizing 4-
month-old male apoE3, apoE4, and apoE-deﬁcient mice
whose genotypes were conﬁrmed by PCR analysis [13, 21].
All experiments were approved by the Tel Aviv University
Animal Care Committee, and every eﬀort was made to
minimize animal usage and reduce animal stress. Alzet
miniosmotic pumps (model 2001, which deliver their con-
tents at 0.25μl/h for up to 14 days) were loaded with the
neprilysin inhibitor thiorphan (0.5mM; Sigma) in artiﬁcial
cerebrospinal ﬂuid containing 1mM ascorbic acid or with
a similar solution without thiorphan “sham.” The Alzet
pumps were implanted with a brain infusion canola inserted
into the lateral ventricle as previously described [13].
2.2. Immunoﬂuorescence and Confocal Microscopy. Thior-
phan and sham-treated mice were anesthetized with
ketamine xylazine at the indicated times following implan-
tation of the Alzet pumps. The brains of these mice were
then processed for immunoﬂourescence after which free-
ﬂoating frozen coronal sections (30μm) were treated with
70% formic acid for 7min and then immunostained as
previouslydescribed[13].Aβ42andoligomerizedAβ42were
detected utilizing rabbit anti-Aβ42 (dilution 1:500 from
Chemicon)andbiotinylatedI-11(dilution1:2000)provided
by Dr. Rakez Kayed, whereas the mitochondrial marker
COX-1 was detected utilizing goat anti-COX-1 (1:400, from
Santa Cruz Biotechnology). The bound primary antibodies
were then visualized by incubating the sections with the
appropriate ﬂuorescently labeled second antibody, or with
ﬂuorescently labeled streptavidin as previously described
[13]. The sections (between bregma −2.0 and −3.0) were
visualized using a confocal scanning laser microscope (Zeiss,
LSM 510). Images (1024 × 1024 pixels) were obtained by
averaging eight scans per slice. Control experiments revealed
no staining in stained sections lacking the ﬁrst antibody. The
intensities of immunoﬂuorescence staining, expressed as the
percentage of the area stained, were calculated utilizing the
Image-Pro Plus system (version 5.1, Media Cybernetics) as
previously described [13]. Two sections were analyzed per
brain, and each staining was performed at least twice. All
the images for each immunostaining were obtained under
identical conditions, and their quantitative analyses were
performed with no further handling. Moderate adjustments
for contrast and brightness were performed on the images
when the ﬁgures were prepared but were the same for the
images of the diﬀerent mouse groups. For the Aβ42 and
I-11 and the COX-1 and Aβ42 double labeling colocalization
experiments, each image was ﬁrst analyzed separately to
determine the percentage of the area stained and then to
determine the percentage of the area of the two images that
colocalize. Measurements of the contribution of stochastic
processes to the co-localization data, which were performed
by shifting the channels of one of the images laterally by
1μm2, revealed that the contribution of stochastic processes
in all the experiments was negligible.
2.3. Immunoblot Analysis. Hippocampi were homogenized
(20%w/v) in PBS, pH 7.4, with protease inhibitor cocktail
(Roche, # 1 836 153) and centrifuged at 10,000rpm for
5min, after which the supernatant (PBS extract) was col-
lected. The resulting pellet was extracted by resuspension in
an equal volume of 10mM Tris pH 7.6 containing 150mM
NaCl, 2mM EDTA, protease inhibitor cocktail (Roche), and
1% NP-40, after which it was centrifuged for 5min at
10,000rpm and the resulting supernatant (NP-40 extract)
was collected. SDSgel electrophoresis utilizing 12% SDSand
immunoblotting with mAb 266 (Elan pharmaceuticals) were
then performed as previously described [19]. Intensities of
the immunoblot bands were quantiﬁed by using EZQuant-
Gel software (EZQuant, Tel-Aviv, Israel).
2.4. Statistical Analysis. It was performed using SPSS version
14. The eﬀects of treatment in the apoE-deﬁcient mice (e.g.,
sham and thiorphan-treated mice) and in the thiorphan-
treated apoE3-,apoE4-, and apoE-deﬁcientmice atthe7-day
time point were each analyzed by one-way ANOVA. In the
10-day experiment, in which both sham- and thiorphan-
treated mice in all three mouse groups were investigated, the
results were analyzed by two-way ANOVA. When appro-
priate, these results were further subjected to post hoc
analysis byStudent’st-testutilizingBonferronicorrectionfor
multiple comparisons.
3.Results
Immunoﬂuorescence measurements of the levels of Aβ42
in hippocampal CA1 neurons of apoE-deﬁcient mice and
their comparison to those of the corresponding apoE3 and
apoE4 targeted replacement mice are depictedin Figure 1(a).
As shown, the Aβ42 levels of the apoE deﬁcient mice were
not aﬀected by the thiorphan treatment at day 7; they wereInternational Journal of Alzheimer’s Disease 3
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Figure 1: The eﬀects of apoE3, apoE4, and apoE deﬁciency on the levels of Aβ42 and oligomerized Aβ42 in CA1 hippocampal neurons
following inhibition of neprilysin. ApoE3, apoE4, and apoE-deﬁcient male mice were injected i.c.v. with the neprilysin inhibitor thiorphan
orsham-treated for7days,after which theirbrains were excised andsubjected to anti-Aβ42andanti-I-11immunoﬂuorescence,as described
in “Materials and Methods.” (a) Representative coronal sections of sham- and thiorphan-treated apoE-deﬁcient mice (upper row) and
thiorphan-treated apoE3 and apoE4 mice (lower row) immunostained with anti-Aβ4 2a r es h o w no nt h el e f t( b a r= 50μm). Quantiﬁcation
of the density of Aβ42 staining (mean ± SEM; n = 5–6mice/group in the sham- and thiorphan-treated groups) in the CA1 neurons of the
indicated mice is shown on the right. P<. 05 for the eﬀects of treatment on the three mouse groups by one-way ANOVA. (b) Representative
confocal images of I-11 of the CA1 area of the indicated mouse groups treated for 7 days with thiorphan (left) and quantiﬁcation (right)
of the density of I-11 staining (mean ± SEM; n = 5–6mice/group in the sham- and thiorphan-treated groups) (mean ± SEM; n = 4–5).
P<. 03 for the eﬀect of treatment on the three mousegroups by one-way ANOVA. (c) Representative masked oligo-Aβ42 images of the CA1
area of the indicated mouse groups treated for 7 days with thiorphan (left) and quantiﬁcation (right) of the density of oligo-Aβ42 staining
(mean ± SEM; n = 5–6mice/group in the sham- and thiorphan-treated groups). P<. 05 for the eﬀect of treatment on the three mouse
groups by one-way ANOVA.4 International Journal of Alzheimer’s Disease
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Figure 2: The eﬀects of apoE3, apoE4, and apoE deﬁciency on the levels of Aβ42 and oligomerized Aβ42 in CA1 hippocampal neurons
followinginhibition ofneprilysin.ApoE3-, apoE4- and apoE-deﬁcient malemice were injected i.c.v.with the neprilysin inhibitorthiorphan;
orsham-treated for10 days, after which their brains were excised and subjected to anti-Aβ42 andanti-I-11 immunﬂuorescence, as described
in “Materials and Methods.” (a) Representative coronal sections of sham- and thiorphan-treated apoE-deﬁcient mice (upper row) and
thiorphan-treated apoE3 and apoE4 mice (lower row) immunostained with anti-Aβ4 2a r es h o w no nt h el e f t( b a r= 50μm). Quantiﬁcation
of the density of Aβ42 staining (mean ± SEM; n = 4–5 mice/group) in the CA1 neurons of the indicated mice is shown on the right
(empty and ﬁlled bars correspond, resp., to sham- and thiorphan-treated mice). P<. 02 for the eﬀects of treatment on the three mouse
groups by two-way ANOVA. (b) Representative confocal images of I-11 of the CA1 area of the indicated mouse groups treated for 10 days
with thiorphan (left) and quantiﬁcation (right) of the density of I-11 staining (mean ± SEM; n = 4 – 5m i c e / g r o u p ) .E m p t ya n dﬁ l l e db a r s
correspond, respectively, to sham-andthiorphan-treated miceandP<. 02fortheeﬀect oftreatment bytwo-wayANOVA.(c)Representative
maskedoligo-Aβ42imagesoftheCA1 area oftheindicated mousegroups treated for10dayswiththiorphan(left) andquantiﬁcation(right)
of the density of oligo-Aβ42 staining (mean ± SEM; n = 4–5mice/group). Empty and ﬁlled bars correspond, respectively, to sham- and
thiorphan-treated mice and P<. 02 for the eﬀect of treatment by two-way ANOVA.International Journal of Alzheimer’s Disease 5
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Figure 3: Aβ42 immunoblot of the hippocampal CA1 ﬁeld of
apoE4, apoE3, and apoE-deﬁcient mice. The mice were treated
for 10 days with thiorphan after which they were killed and their
hippocampus was extracted and immunoblotted with the anti-
Aβ42 Ab 266 as described in “Materials and Methods.” Membrane
bound NP40 extractable Aβ42 (apparent molecular weight 4.5kD)
is shown in the upper panels whereas the corresponding PBS
extractable soluble Aβ42 is shown in the lower panels.
similar to those of the thiorphan-treated apoE3 mice and
were signiﬁcantly lower than those of the thiorphan-treated
apoE4 mice (P<. 05; Figure 1(a)). Further measurements
of the eﬀects of apoE on the accumulation of oligomerized
Aβ42 were performed utilizing Ab I-11, which is directed
speciﬁcally at the backbone of amyloid oligomers [22,
23]. This revealed that at day 7, and in accordance with
the Aβ42 results, the thiorphan treatment induced I-11
immunoreactivity to accumulate in the CA1 neurons of the
apoE4 but not in those of either the apoE3 mice or the
apoE-deﬁcient mice (P<. 03; Figure 1(b)). The I-11 and
Aβ42 immunoreactivities of the individual apoE4 mice were
highly correlated (R2 = 0.9). I-11 recognizes amyloid-like
structures derived from Aβ as well as non-Aβ peptides [23].
Accordingly, the levels of I-11 in the diﬀerent mouse groups
that correspond to oligomerized Aβ42 were determined by
doublelabeling confocal experiments utilizing I-11 and anti-
Aβ42. This revealed signiﬁcant co-localization of these stains
and of their merged image, which we will term here “oligo-
Aβ42,” in the CA1 neurons of the apoE4 mice (Figure 1(c)).
In contrast, and in agreement with the single labeling exper-
iments, the levelsofoligo-Aβ42 in CA1neurons of the apoE-
deﬁcient and apoE3 mice were similar and low.
Additional measurements of the levelsof Aβ42, I-11, and
oligo-Aβ42 in the diﬀerent mouse groups were also per-
formed on day 10 after the thiorphan treatment began. This
revealed that, unlike at the earlier time point, the levels of
Aβ42, I-11, and oligo-Aβ42 of the apoE-deﬁcient mice were
now elevated and comparable to those observed with the
apoE4 mice (Figure 2; P<. 02 for the eﬀect of treatment
by 2-way ANOVA). Importantly, the corresponding levels
of Aβ42, I-11, and oligo-Aβ42 in the apoE3 mice were
not increased by the thiorphan treatment even at 10 days
(Figure 2).
Previous immunoblot experiments utilizing hippocam-
pal homogenates revealed that the thiorphan-treated apoE3
and apoE4 mice have similar Aβ42 levels but that in the
apoE4 most of the Aβ42 is membrane-bound whereas in
the apoE3 mice it is soluble [19]. Accordingly, we next
investigated the extent to which apoE deﬁciency aﬀects the
levels and solubility of the accumulated Aβ42. As shown in
Figure 3the levelsofthemembrane-bound NP40 extractable
Aβ42 and of the soluble PBS extractable Aβ42 pools of the
apoE-deﬁcient mice were intermediate to those of the apoE3
and apoE4 mice. Furthermore, the total levels of soluble and
insolublepoolsweresimilarintheapoE4,apoEdeﬁcient,and
apoE3 mice (resp., 100 ± 30%, 91 ± 17% and 91 ± 18%).
Comparison of these results to the immunoﬂourescence
ﬁndings (compare Figures 2 and 3 both of which were
obtained at day 10) revealed that the relative levels of the
NP40 extractable Aβ42 pools and of the accumulation of
intracellular Aβ42 in thediﬀerentmice groups havethe same
rank order(apoE4 > apoE deﬁcient > apoE3) suggesting that
the accumulated intracellular Aβ42 is membrane bound.
We have recently shown by electron microscopy that the
speciﬁc accumulation of Aβ42 in CA1 neurons of apoE4
mice following inhibition of neprilysin is associated with
marked mitochondrial deformation and with the colocaliza-
tion of Aβ in the aﬀected mitochondria [19]. Complemen-
tary immunoﬂuorescence confocal microscopy experiments
revealed that the mitochondrial pathology is associated with
increased levels of mitochondrial COX-1 immunoreactivity
and with the colocalization of Aβ42 with COX-1 [19].
Utilizing COX-1 as a marker of mitochondrial pathology,
we investigated the extent to which inhibition of neprilysin
in the mice aﬀects their mitochondria. This revealed that
mitochondrial pathology at 7 days, like the accumulation
of Aβ42 and oligo-Aβ42, occurs only in the apoE4 mice
(not shown). In contrast, at day 10 it occurred in both the
apoE4 and the apoE-deﬁcient mice but not in the apoE3
mice (Figure 4(a)). Furthermore, the magnitude of the
mitochondrial eﬀect and the levels of Aβ42 in the apoE-
deﬁcient were both similarly lower in the apoE-deﬁcient
than the apoE4 mice (compare Figures 2 and 4). Co-
localization confocal microscopy revealed that the Aβ42
which accumulates in CA1 neurons of the apoE-deﬁcient
mice, like that of the corresponding apoE4 mice [19],
colocalizes with mitochondria (Figure 4(b)). The ﬁndings
that the levels of mitochondrial pathology and of Aβ42 and
oligomerized Aβ42 in the CA1 neurons of the diﬀerent mice
groups correlate suggest that the main and rate-limiting
eﬀect of apoE4 on the mitochondria is due to stimulation
of the accumulation of Aβ42 and oligomerized Aβ42.
4.Discussion
The present study revealed that apoE4 triggers the accumu-
lation ofAβ42 in hippocampal CA1neuronsduring theearly
phase (i.e., 7 days), following activation of the amyloid cas-
cade in vivo and that this eﬀect is speciﬁc to apoE4 and does
not occur in either apoE3 or apoE-deﬁcient mice. This eﬀect
reﬂects diﬀerences in the extent of accumulation of Aβ42,
since the total hippocampal Aβ42 contents, determined by
immunoblots, were similarly elevated following inhibition
of neprilysin in the ApoE3 and apoE4 mice [19]a n di nt h e
apoE-deﬁcient ones (not shown). The present ﬁndings are in
accordance with previous in vitro cell culturestudies[24–26]
and suggest that the rate-limiting step in the apoE4-driven
accumulation of Aβ42 is due to a gain of function.6 International Journal of Alzheimer’s Disease
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Figure 4: The eﬀects of apoE3, apoE4, and apoE deﬁciency on the mitochondria of hippocampal CA1 neurons following inhibition of
neprilysin. ApoE3, apoE4, and apoE-deﬁcient male mice were injected i.c.v. with the neprilysin inhibitor thiorphan or sham-treated for
10 days, after which their brains were excised and subjected to COX-1 immunoﬂuoresence as described in “Materials and Methods.” (a)
Representative coronal sections of sham- and thiorphan-treated apoE-deﬁcient mice (upper row) and thiorphan-treated apoE3 and apoE4
mice (lower row) immunostained with anti-COX-1 are shown on the left (bar = 50μm). Quantiﬁcation of the density of staining (mean ±
SEM; n = 4–5mice/group in the sham- and thiorphan-treated groups) in the CA1 neurons of the indicated mice is shown on the right
(empty and ﬁlled bars correspond, resp., to sham- and thiorphan-treated mice). P<. 03 for the eﬀects of treatment on the three mouse
groups by Two-wayANOVA. (b) Representative confocalimagesoftheco-localizationofAβ42andCOX-1 intheCA1 area ofapoE-deﬁcient
mice treated with thiorphan for 10 days.
The ﬁnding that the I-11 immunoreactivity levels of the
CA1 neurons in the apoE-deﬁcient mice, like their Aβ42
levels, did not rise during the initial 7 days following the
thiorphan treatment (Figure 1(b)) is in accordance with the
observationthat thesemoleculescolocalizein the thiorphan-
treated apoE4 mice (Figure 1(c)). Moreover, it suggests that
thiorphan treatment in the apoE-deﬁcient mice does not
stimulate the production of non-Aβ amyloid molecules in
the CA1 neurons.
At longer time intervals, following activation of the
amyloid cascade by inhibition of neprilysin (i.e., 10 versus
7 days), this treatment also induces the accumulation of
oligomerized Aβ42 in the CA1 neurons of the apoE-deﬁcient
mice but not those of the apoE3 mice (Figure 2). This may
be a reﬂection of time-dependent diﬀerences in the apoE
dependenciesofthekineticsofAβ42accumulation,suchthat
Aβ42 accumulation in the apoE-deﬁcient mice is delayed
relative to that observed with the apoE4 mice. Alternatively,
since the extent of Aβ42 accumulation is determined by the
interplay between uptake and clearance, it is also possible
that apoE-related eﬀectson the clearance of Aβ42 contribute
signiﬁcantly to the observed eﬀects at 10 days. Indeed, it
has recently been shown that the clearance of Aβ is more
eﬀective in apoE3 mice than in apoE4- and apoE-deﬁcient
mice [1, 27, 28]. This suggests that the observation that the
levels of Aβ42 are particularly low in the thiorphan-treated
a p o E 3m i c ea t1 0d a y s( F i g u r e2(a)) may be due, at least
in part, to enhanced clearance of Aβ42 by apoE3. Further
studies are required for unraveling the role of clearance-
related mechanisms in mediating the eﬀects of the diﬀerent
apoE isoforms and of apoE deﬁciency on the intracellular
levels of Aβ42.
Examination of the eﬀects of apoE-deﬁciency on the
oligomerization of Aβ42 revealed that whereas the levels
of Aβ42 in the apoE-deﬁcient mice at 10 days are lower
than those of the apoE4 mice (Figure 2(a)), the two mice
groupshavesimilarlevelsofoligomerizedAβ42(Figures2(b)
and 2(c)). This suggests that either apoE does not play a
rate-limiting role in the early stages of oligomerization of
Aβ42 which are detected with I-11, or that apoE deﬁciency
has an indirect stimulatory eﬀect on the aggregation of
Aβ42.International Journal of Alzheimer’s Disease 7
The levels of Aβ42 and oligomerized Aβ42 in the CA1
neurons of the diﬀerent mice groups and time points reveal
that they correlate positively with the corresponding levels
of mitochondrial pathology (Figures 1, 2, 4). This suggests
that the limiting step in the observed eﬀects of apoE4 on
the mitochondria is stimulation of the accumulation and the
oligomerization of Aβ42. One implication of this conclusion
is that the eﬀects of apoE4 on the mitochondria are not
mediated via direct eﬀects of apoE4 on the mitochondria,
which is consistent with our recent ﬁnding that the apoE4
which accumulates in CA1 neurons following inhibition of
neprilysin does not colocalize with mitochondria [19].
The mechanisms underlying the accumulation of Aβ42
and oligomerized Aβ42 in the mitochondria are not fully
understood. Since Aβ42 also accumulates in the lysosome
of the CA1 neurons of the neprilysin inhibited apoE4 mice
[19], it is possible that Aβ42 reaches the cytoplasm and
the mitochondria via the lysosomal pathway and lysosomal
leakage. Alternately since extracellularly applied Aβ42 accu-
mulates in the mitochondria of neuronal cultures [29], it is
also possible that the extracelluar Aβ42 which accumulates
following inhibition of neprilysin reaches the mitochondria
via this route.
In conclusion, the present ﬁndings show that the
isoform-speciﬁc accumulation of Aβ42 and oligomerized
Aβ42 in hippocampal neurons, following activation of the
amyloid cascade in vivo, is mediated by a gain-of-function
property of apoE4. Furthermore, since the resulting mito-
chondrialpathologycorrelateswiththelevelsofaccumulated
Aβ42 and oligomerized Aβ42, this suggests that the overall
pathological eﬀects of apoE4 in this system are driven by
the eﬀects of apoE4 on the accumulation of Aβ42 and that
consequently an anti-apoE4 therapeutic strategy may be
eﬀective in counteracting the synergistic pathological eﬀects
of apoE4 and Aβ42.
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